Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis.
antibiotic
cancer
immune checkpoint inhibitors
meta-analysis
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
13 May 2020
13 May 2020
Historique:
received:
31
03
2020
revised:
03
05
2020
accepted:
11
05
2020
entrez:
17
5
2020
pubmed:
18
5
2020
medline:
18
5
2020
Statut:
epublish
Résumé
Antibiotics (ABs) are common medications used for treating infections. In cancer patients treated with immune checkpoint inhibitors (ICIs), concomitant exposure to ABs may impair the efficacy of ICIs and lead to a poorer outcome compared to AB non-users. We report here the results of a meta-analysis evaluating the effects of ABs on the outcome of patients with solid tumours treated with ICIs. PubMed, the Cochrane Library and Embase were searched from inception until September 2019 for observational or prospective studies reporting the prognoses of adult patients with cancer treated with ICIs and with or without ABs. Overall survival (OS) was the primary endpoint, and progression-free survival (PFS) was the secondary endpoint. The effect size was reported as hazard ratios (HRs) with a 95% confidence interval (CI) and an HR > 1 associated with a worse outcome in ABs users compared to AB non-users. Fifteen publications were retrieved for a total of 2363 patients. In the main analysis (
Identifiants
pubmed: 32414103
pii: jcm9051458
doi: 10.3390/jcm9051458
pmc: PMC7290584
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Immunother Cancer. 2019 Jul 10;7(1):176
pubmed: 31292005
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295966
Oncoimmunology. 2019 Feb 18;8(4):e1568812
pubmed: 30906663
Anticancer Res. 2019 Oct;39(10):5675-5682
pubmed: 31570466
Ann Oncol. 2018 Dec 1;29(12):2396-2398
pubmed: 30307530
Lung Cancer. 2019 Apr;130:10-17
pubmed: 30885328
Oncoimmunology. 2019 Sep 23;8(12):e1665973
pubmed: 31741763
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Lung Cancer. 2019 Jun;132:72-78
pubmed: 31097097
Oncologist. 2020 Jan;25(1):55-63
pubmed: 31292268
Oncol Lett. 2019 Mar;17(3):2946-2952
pubmed: 30854072
J Immunother Cancer. 2019 Sep 5;7(1):242
pubmed: 31488205
Oncotarget. 2018 Mar 27;9(23):16512-16520
pubmed: 29662663
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
JAMA Oncol. 2019 Sep 12;:
pubmed: 31513236
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Oncoimmunology. 2018 Aug 20;7(11):e1507670
pubmed: 30377571
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Anticancer Res. 2017 Jun;37(6):3195-3200
pubmed: 28551664
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Crit Rev Oncol Hematol. 2019 Nov;143:139-147
pubmed: 31634731